Journal
BRITISH JOURNAL OF PHARMACOLOGY
Volume 157, Issue 6, Pages 922-930Publisher
WILEY
DOI: 10.1111/j.1476-5381.2009.00278.x
Keywords
arginase; arginase inhibitors; arginine; cancer; endothelial; genetic knockout; nitric oxide; polyamines; vascular
Categories
Funding
- NIH [GM57384, GM64509]
Ask authors/readers for more resources
As arginine can serve as precursor to a wide range of compounds, including nitric oxide, creatine, urea, polyamines, proline, glutamate and agmatine, there is considerable interest in elucidating mechanisms underlying regulation of its metabolism. It is now becoming apparent that the two isoforms of arginase in mammals play key roles in regulation of most aspects of arginine metabolism in health and disease. In particular, work over the past several years has focused on the roles and regulation of the arginases in vascular disease, pulmonary disease, infectious disease, immune cell function and cancer. As most of these topics have been considered in recent review articles, this review will focus more closely on results of recent studies on expression of the arginases in endothelial and vascular smooth muscle cells, post-translational modulation of arginase activity and applications of arginase inhibitors in vivo. British Journal of Pharmacology (2009) 157, 922-930; doi:10.1111/j.1476-5381.2009.00278.x; published online 5 June 2009
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available